OpenScience.ink

3 weeks ago • Federal practitioner : for the health care professionals of the VA, DoD, and PHS

Increasing Doses of Semaglutide Under the Skin May Lower Insulin Use in Type 2 Diabetes PatientsEfficacy of Subcutaneous Semaglutide Dose Escalation in Reducing Insulin in Patients With Type 2 Diabetes.

Article

3 weeks ago • Cureus

Blood Pressure Control in U.S. Adults with High Blood Pressure, Compared by Use of GLP-1 Receptor MedicinesBlood Pressure Control Among U.S. Adults With Hypertension, Stratified by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use: Evidence From the National Health and Nutrition Examination Survey, 2017-2020.

Article

3 weeks ago • Journal of neurosurgery. Spine

Use of GLP-1 drugs linked to lower rates of bone fusion problems and swallowing difficulties after neck spine surgery, with effects changing over timeGLP-1 agonist use and lower rates of pseudarthrosis and dysphagia following anterior cervical discectomy and fusion surgery, with time-dependent effects.

Article

3 weeks ago • Cureus

Weight Regain After Weight Loss Surgery: Medications That Affect Digestion Hormones and the Changing Role of Follow-Up SurgeryWeight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery.

Article

3 weeks ago • Pain

Glucagon-like peptide-1 treatment is linked to less nerve damage and pain in type 2 diabetesGlucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes.

Article

3 weeks ago • Diabetes, obesity & metabolism

Link Between GLP-1 Receptor Agonist Drugs and Diabetic Eye DiseaseAssociation of GLP1-Receptor Agonists With Diabetic Retinopathy.

Article

3 weeks ago • Cardiovascular drugs and therapy

Ongoing Inflammation Risk in Heart Failure with Preserved Pumping: Using Multiple Organs to Track, Select Patients, and Evaluate Treatments Over TimeCandidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal.

Article

3 weeks ago • Science progress

Semaglutide use linked to kidney health in adults with inherited kidney cyst diseaseAssociation of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study.

Article

3 weeks ago • The Laryngoscope

Hair Loss Without Scarring in Adults Using GLP-1 Medications: A Matched Group StudyNonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.

Article

3 weeks ago • Cureus

Comparing heart-related side effects of Semaglutide and Tirzepatide using FDA safety reports from 2022 to 2026Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).

Article

3 weeks ago • Physiology & behavior

How Glucagon-Like Peptide-1 Receptor Agonists Affect Taste and Eating BehaviorThe Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior.

Article

3 weeks ago • Diabetes, obesity & metabolism

Heart and kidney risks and safety of GLP-1 medicines in type 2 diabetes patients with BMI under 27Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.

Article

3 weeks ago • Parkinsonism & related disorders

How GLP-1 slows stomach emptying and affects levodopa absorption in Parkinson's disease: Clinical significanceGLP-1-mediated delay in gastric emptying and impact on levodopa absorption in Parkinson's disease: Clinical implications.

Article

3 weeks ago • Diabetes, obesity & metabolism

Changes in Healthcare Costs for Adults Over 55 with Obesity or Overweight Using Tirzepatide Without DiabetesTrends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.

Article

3 weeks ago • Journal of controlled release : official journal of the Controlled Release Society

Oral nanomicelles targeting two transporters improve semaglutide absorption and metabolism in obesity and diabetesDual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.

Article

3 weeks ago • Drug discovery today

GLP-1 receptor drugs for eye diseases: treatment potential, how they work, and possible safety concernsGLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Article

3 weeks ago • Diabetes, obesity & metabolism

Predicting who responds to GLP-1 or GLP-1/GIP receptor agonist treatmentsResponders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.

Article

3 weeks ago • JAR life

Effects of GLP-1 receptor drugs on adult skeletal muscle and what this means for older adultsGLP-1 receptor agonist therapy and skeletal muscle: A narrative review synthesizing adult evidence with implications for older adults.

Article

4 weeks ago • npj metabolic health and disease

Rethinking obesity treatment with new GLP-1 receptor drugsReappraising obesity management in the GLP-1 receptor agonist era.

Letter

4 weeks ago • Diabetes care

Heart and Metabolism Effects of Drugs Targeting Both GLP-1 and Glucagon ReceptorsCardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Article

4 weeks ago • World journal of methodology

Glucagon-like receptor-1 agonists and their link to impotence: A combined analysisGlucagon-like receptor-1 agonists and impotence: A meta-analysis.

Article

4 weeks ago • Diabetes care

New Developments in Diabetes Treatments in AsiaRecent Advances in Diabetes Therapies in Asia.

Article

4 weeks ago • World journal of methodology

Communication between the pancreas and liver, new molecular signals, and potential treatments by 2025Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs.

Article

1 month ago • JAMA

GLP-1 Gut Hormones: From Discovery to Major Public Health Impact – A Conversation with Jens Juul Holst and Lotte Bjerre KnudsenGLP-1s-From Gut Hormone Discovery to a Public Health Revolution: A Healthy Dialogue With Jens Juul Holst and Lotte Bjerre Knudsen.

Video-Audio Media

1 month ago • Surgery

Why patients choose weight-loss surgery even when using diabetes-related medicationsDrugs are not cutting it: Patient motivations for metabolic and bariatric surgery despite glucagon-like peptide-1 use.

Article

1 month ago • Journal of molecular endocrinology

Changes in gut structure and hormone-producing cells after stomach surgery in male miceAn analysis of intestinal morphology and incretin-producing cells after sleeve gastrectomy in male mice.

Article

← prevpage 14 of 14next →

GLP-1 Therapies Research Papers